SRx Health Solutions Provides Response Related to Unusual Market Trading Activity Received by the NYSE American Exchange
SRx Health Solutions (NYSE American: SRXH) said the NYSE American notified the company of unusual trading activity in its common shares on November 6, 2025. The company stated it is not aware of any material developments beyond what has been publicly disclosed and reminded investors to rely on its SEC filings and press releases. The release was issued pursuant to Section 401(d) of the NYSE American Company Guide and includes a standard forward-looking statements caution.
Contact information for CEO Kent Cunningham and investor relations via KCSA Strategic Communications is provided for further inquiries.
SRx Health Solutions (NYSE American: SRXH) ha comunicato che la NYSE American ha notificato alla società di attività di trading insolite nelle sue azioni ordinarie in data 6 novembre 2025. L'azienda ha dichiarato di non essere a conoscenza di alcun sviluppo sostanziale diverso da quanto pubblicamente divulgato e ha ricordato agli investitori di fare affidamento sui propri depositi SEC e comunicati stampa. Il comunicato è stato rilasciato ai sensi della Sezione 401(d) della NYSE American Company Guide e comprende una comune avvertenza su dichiarazioni previsionali.
Le informazioni di contatto per il CEO Kent Cunningham e per le relazioni con gli investitori tramite KCSA Strategic Communications sono fornite per ulteriori richieste.
SRx Health Solutions (NYSE American: SRXH) dijo que NYSE American notificó a la empresa de actividad de negociación inusual en sus acciones comunes el 6 de noviembre de 2025. La compañía declaró que no tiene constancia de desarrollos materiales más allá de lo que ya se ha divulgado públicamente y recordó a los inversores que deben confiar en sus presentaciones ante la SEC y comunicados de prensa. El comunicado se emitió de conformidad con la Sección 401(d) de la Guía de la Empresa de NYSE American y incluye una advertencia estándar sobre declaraciones a futuro.
Se proporcionan las informaciones de contacto para el CEO Kent Cunningham y para las relaciones con los inversores a través de KCSA Strategic Communications para consultas adicionales.
SRx Health Solutions (NYSE American: SRXH)은 NYSE American이 일반 주식의 비정상적 거래 활동에 대해 2025년 11월 6일 회사에 통지했다고 밝혔다. 회사는 공개적으로 공개된 내용 외에 중대한 발전 사항을 알고 있지 않으며 투자자들에게 SEC 서류 및 보도 자료에 의존할 것을 상기시켰다. 본 보도자료는 NYSE American Company Guide의 제401(d)조에 따라 발행되었으며 표준적인 미래지향적 진술의 주의사항을 포함한다.
추가 문의를 위한 CEO Kent Cunningham과 KCSA Strategic Communications를 통한 투자자 관계의 연락처 정보가 제공된다.
SRx Health Solutions (NYSE American: SRXH) a déclaré que le NYSE American a informé la société d'une activité de négociation inhabituelle sur ses actions ordinaires le 6 novembre 2025. La société a indiqué qu'elle n'est pas au courant de développements importants au-delà de ce qui a été divulgué publiquement et a rappelé aux investisseurs de s'appuyer sur ses dépôts SEC et communiqués de presse. Le communiqué a été publié conformément à l'article 401(d) du NYSE American Company Guide et comprend une mise en garde standard concernant les déclarations prospectives.
Les informations de contact pour le PDG Kent Cunningham et les relations investisseurs via KCSA Strategic Communications sont fournies pour toute demande supplémentaire.
SRx Health Solutions (NYSE American: SRXH) teilte mit, dass die NYSE American das Unternehmen über unkonventionelles Handelsvolumen seiner Stammaktien am 6. November 2025 informiert hat. Das Unternehmen erklärte, dass es sich keiner wesentlichen Entwicklungen jenseits dessen bewusst sei, was öffentlich bekannt gemacht wurde, und erinnerte Investoren daran, sich auf seine SEC-Unterlagen und Pressemitteilungen zu verlassen. Die Mitteilung wurde gemäß Abschnitt 401(d) des NYSE American Company Guide veröffentlicht und enthält einen standardmäßigen Hinweis zu zukunftsgerichteten Aussagen.
Kontaktinformationen für den CEO Kent Cunningham und die Investor Relations über KCSA Strategic Communications werden für weitere Anfragen bereitgestellt.
SRx Health Solutions (NYSE American: SRXH) ذكرت أن بورصة NYSE American أبلغت الشركة عن أنشطة تداول غير عادية في أسهمها العادية في 6 نوفمبر 2025. وذكرت الشركة أنها ليست على علم بأي تطورات جوهرية بخلاف ما تم الإفصاح عنه علنًا وتذكير المستثمرين بالاعتماد على ملفات SEC وبياناتها الصحفية. صدر البيان وفقاً للقسم 401(d) من دليل شركة NYSE American ويشمل تحذيراً قياسياً بخصوص التصريحات المستقبلية.
توفر معلومات الاتصال بالرئيس التنفيذي Kent Cunningham ولعلاقات المستثمرين عبر KCSA Strategic Communications لاستفسارات إضافية.
- None.
- None.
TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its Common Shares on November 6, 2025. The Company is not aware of any material developments in its business or affairs beyond those that have been publicly disclosed. Investors should rely solely on the Company’s filings with the SEC and its press releases.
The Company is issuing this press release pursuant to Section 401(d) of the NYSE American Company Guide.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com
FAQ
What did SRx Health Solutions (SRXH) say about unusual trading on November 6, 2025?
Does SRx Health Solutions (SRXH) report any material developments after the unusual trading notice?
Where should investors look for official information about SRx Health Solutions (SRXH)?
Why did SRx Health Solutions (SRXH) issue this press release under NYSE rules?
Who can investors contact for more information about SRx Health Solutions (SRXH)?
